Great news out of Washington, D.C.! Late last night, lawmakers released H.R. 2882, the Further Consolidated Appropriations Act, 2024, including $25 million for NF research through the Congressionally Directed Medical Research Program – Neurofibromatosis Research Program (CDMRP-NFRP) for Fiscal Year 2024. This funding is an important boost to our cause, driving essential research aimed at better understanding, diagnosing, and treating neurofibromatosis and schwannomatosis (NF1, NF2-SWN, and SWN).
This is a result of our ongoing advocacy in support of collaborative innovations between the public and private sectors – for example, the incredible NF Clinical Trials Consortium, a shining example of effective resources and expertise advancing NF research forward.
We’re proud to have worked alongside you – the NF community – to advocate for this funding and are thankful to Congress for its longstanding support of the CDMRP-NFRP. The bill has been negotiated by bipartisan lawmakers in the House and Senate and will be considered by both chambers over the coming days. We’ll continue to provide updates as it progresses through Congress.
Together, we are laying the groundwork for breakthroughs that will benefit both NF patients as well as far beyond the NF community!
